Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 27, 2020 07:30 ET | Source: Biogen Inc.; Sage Therapeutics

Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders

Biogen and Sage enter into an agreement to jointly develop and commercialize zuranolone and SAGE-324 in the U.S.Biogen to receive exclusive license to develop and commercialize zuranolone and SAGE-324...
November 18, 2020 07:00 ET | Source: Biogen Inc.

Samsung Bioepis and Biogen Announce FDA Filing Acceptance of SB11, A Proposed Biosimilar Referencing Lucentis® (ranibizumab)

INCHEON, South Korea and CAMBRIDGE, Mass., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA)...
November 16, 2020 07:30 ET | Source: Biogen Inc.

Biogen Ranked #1 Biotechnology Company by Dow Jones Sustainability World Index for an Industry Record 5th Time; Recognition Reflects Longstanding ESG Leadership

Biogen earns top scores on areas including access to medicine, talent attraction, innovation management and climate performance and reportingIn 2013 Biogen became the 1st U.S. biotech company to...
November 06, 2020 20:15 ET | Source: Biogen Inc.

Update on FDA Advisory Committee’s Meeting on Aducanumab in Alzheimer’s Disease

CAMBRIDGE, Mass. and TOKYO, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Today, the U.S. Food and Drug Administration (FDA) Peripheral and Central Nervous System Drugs Advisory Committee voted 1 yes, 8 no and...
November 03, 2020 07:30 ET | Source: Biogen Inc.

Biogen to Present Positive Phase 2 Systemic Lupus Erythematosus Data at American College of Rheumatology 2020 Meeting

In Phase 2 LILAC study, BIIB059 demonstrated a statistically significant reduction in joint disease activity compared to placebo in systemic lupus erythematosus patientsPositive results build on...
October 30, 2020 07:00 ET | Source: Biogen Inc.

European Medicines Agency Accepts Biogen’s Aducanumab Marketing Authorization Application for Alzheimer's Disease

If approved, aducanumab would become the first therapy to reduce the clinical decline of Alzheimer’s disease and to meaningfully change the course of Alzheimer’s disease CAMBRIDGE, Mass. and...
October 06, 2020 07:00 ET | Source: Biogen Inc.; Samsung Bioepis

Samsung Bioepis and Biogen Announce EMA Filing Acceptance of SB11, a Proposed Biosimilar Referencing Lucentis® (ranibizumab)

INCHEON, South Korea and CAMBRIDGE, Mass., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the European Medicines Agency (EMA) has...
September 14, 2020 07:30 ET | Source: Biogen Inc.

Biogen to Invest $250 Million in a 20-year Initiative to Eliminate its Use of Fossil Fuels and Improve Public Health

After achieving carbon neutrality in 2014, Biogen further bolsters its action against climate change with the goal to become fossil fuel free by 2040 and initiates research collaborations with global...
September 11, 2020 08:01 ET | Source: Biogen Inc.

New Data at ACTRIMS-ECTRIMS Meeting Showcase Safety and Efficacy of Biogen’s Industry-Leading MS Portfolio

New data from ongoing Phase 3 study further define the effectiveness and improved GI tolerability of VUMERITY® (diroximel fumarate)Real-world findings evaluate quality of life benefits associated with...
September 08, 2020 07:30 ET | Source: Biogen Inc.

New Biogen Data Presented at ACTRIMS-ECTRIMS Advance Understanding of Clinical and Health Disparities in MS

Data highlights socio-demographic and clinical disparities to help raise awareness of health inequities and inform future treatment planningReal-world data from MS PATHS identifies clinically relevant...